Phase III trials in multiple myeloma, including plitidepsin, elotuzumab, carfilzomib, masitinib, and panobinostat.
Powell Reviews Updated IO/TKI Data and AE Management in Endometrial Cancer
April 18th 2024During a Case-Based Roundtable® event, Matthew A. Powell, MD, discussed the case of a patient with advanced endometrial cancer treated with lenvatinib plus pembrolizumab who experienced grade 2 treatment-related hypertension.
Read More
Savona Discusses First-Line JAK Inhibition for Patients With Myelofibrosis at Risk of Anemia
April 17th 2024During a Case-Based Roundtable® event, Michael Savona, MD, and participants discussed the case of a patient with myelofibrosis and moderate anemia receiving JAK inhibitor therapy.
Read More